ArticlemAbs2026

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.

Welbeck Danquah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.